Purpose: The aim of this study was to determine the prophylactic effects of cabergoline on ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval. Methods: A total of 187 women underwent controlled ovarian stimulation usinggonadotropin releasing hormone (GnRH) agonist long protocol or flexible GnRH antagonist protocol for in vitro fertilization. They responded excessively to ovulation induction, and fresh embryo transfers were canceled. Sixty-one patients in the intervention group were administered oral cabergoline (0.5 mg) three times after oocyte retrieval (day 0, 2, and 4 following the oocyte retrieval). Ultrasonography and blood examination were performed on the seventh day following oocyte retrieval. The main outcomes measured were the incidence of OHSS, estimated ovarian volumes, ascites, hematocrits, and white blood cell counts. Results: The incidence of moderate to severe OHSS was lower after cabergoline administration (9.8 vs. 23.0 %, p = 0.03). The ovarian volumes reduced after intervention (96.2 vs. 145.5 cm3, p = 0.008). The reduction was evident in the patients with agonist long protocol (92.1 vs. 167.5 cm3, p = 0.0005). No significant differences were observed for other factors. Conclusions: Cabergoline has a favorable effect on the prevention of moderate to severe OHSS affiliated with ovarian volume reduction.
RCT Entities:
Purpose: The aim of this study was to determine the prophylactic effects of cabergoline on ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval. Methods: A total of 187 women underwent controlled ovarian stimulation using gonadotropin releasing hormone (GnRH) agonist long protocol or flexible GnRH antagonist protocol for in vitro fertilization. They responded excessively to ovulation induction, and fresh embryo transfers were canceled. Sixty-one patients in the intervention group were administered oral cabergoline (0.5 mg) three times after oocyte retrieval (day 0, 2, and 4 following the oocyte retrieval). Ultrasonography and blood examination were performed on the seventh day following oocyte retrieval. The main outcomes measured were the incidence of OHSS, estimated ovarian volumes, ascites, hematocrits, and white blood cell counts. Results: The incidence of moderate to severe OHSS was lower after cabergoline administration (9.8 vs. 23.0 %, p = 0.03). The ovarian volumes reduced after intervention (96.2 vs. 145.5 cm3, p = 0.008). The reduction was evident in the patients with agonist long protocol (92.1 vs. 167.5 cm3, p = 0.0005). No significant differences were observed for other factors. Conclusions: Cabergoline has a favorable effect on the prevention of moderate to severe OHSS affiliated with ovarian volume reduction.
Authors: Raul Gomez; Miguel Gonzalez-Izquierdo; Ralf C Zimmermann; Edurne Novella-Maestre; Isabel Alonso-Muriel; Jose Sanchez-Criado; Jose Remohi; Carlos Simon; Antonio Pellicer Journal: Endocrinology Date: 2006-08-10 Impact factor: 4.736
Authors: Sérgio Reis Soares; Raúl Gómez; Carlos Simón; Juan Antonio García-Velasco; Antonio Pellicer Journal: Hum Reprod Update Date: 2008-04-02 Impact factor: 15.610
Authors: Edurne Novella-Maestre; Carmen Carda; Inmaculada Noguera; Amparo Ruiz-Saurí; Juan Antonio García-Velasco; Carlos Simón; Antonio Pellicer Journal: Hum Reprod Date: 2009-02-03 Impact factor: 6.918